NCT02477579View on ClinicalTrials.gov

A Prospective, Multi-Center, Pivotal Study to Evaluate the Safety and Effectiveness of the NovaCross™ Micro-catheter in Facilitating Crossing Chronic Total Occlusion (CTO) Coronary Lesions

NACompletedINTERVENTIONAL
Enrollment

145

Participants

Timeline

Start Date

May 17, 2015

Primary Completion Date

August 10, 2017

Study Completion Date

August 10, 2017

Conditions
Chronic Total Occlusion of Coronary Artery
Interventions
DEVICE

NovaCross

The NovaCross™ is a guidewire positioning and support microcatheter for improving chronic total occlusion (CTO) crossability. The NovaCross™ gains its supportive characteristics through the use of a unique operator-controlled Nitinol scaffold and an extendable segment, both at its distal tip.

Trial Locations (5)

10032

Columbia University Medical Center/New York Presbyterian Hospital, New York

17403

York Hospital, York

60540

Edward Hospital, Naperville

72205

Central Arkansas Veterans Healthcare System, Little Rock

Unknown

SPZOZ University Hospital in Krakow, Krakow

All Listed Sponsors
lead

Nitiloop Ltd.

INDUSTRY

NCT02477579 - A Prospective, Multi-Center, Pivotal Study to Evaluate the Safety and Effectiveness of the NovaCross™ Micro-catheter in Facilitating Crossing Chronic Total Occlusion (CTO) Coronary Lesions | Biotech Hunter | Biotech Hunter